Holen Sie sich die Stockscreener-App
64.29
2.10%
1.32
Handel nachbörslich:
64.33
0.04
+0.06%
Cg Oncology Inc Aktie (CGON) Neueste Nachrichten
Rosalind Advisors Inc. Grows Holdings in CG Oncology, Inc. $CGON - MarketBeat
Is It Too Late To Consider CG Oncology (CGON) After A 143% One Year Surge? - simplywall.st
CG Oncology stock rallies nearly 32% in a week: Here is why - MSN
CG Oncology stock hits all-time high at 63.9 USD - Investing.com Australia
CG Oncology stock hits all-time high at 63.9 USD By Investing.com - Investing.com South Africa
CG Oncology (NASDAQ:CGON) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
CG Oncology (CGON) Valuation Check After Strong Recent Share Price Momentum - simplywall.st
CG Oncology (NASDAQ:CGON) Sets New 52-Week HighHere's What Happened - MarketBeat
CG Oncology Conference: Credo Posts 75.5% CR in BOND-003, BLA Filing Targeted for 2026 - MarketBeat
JPMorgan Chase & Co. Has $9.18 Million Stock Holdings in CG Oncology, Inc. $CGON - MarketBeat
Replimune Stock Pre-Market (+16%): Sector Momentum Lifts Oncolytic Virus Peers - Trefis
Insider Trends: Is CG Oncology Inc exposed to currency risksJuly 2025 Trade Ideas & Capital Efficient Trade Techniques - baoquankhu1.vn
H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating - Finviz
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale - AOL.com
10 Fastest Growing NASDAQ Stocks to Buy - Insider Monkey
Rafferty Asset Management LLC Lowers Stock Position in CG Oncology, Inc. $CGON - MarketBeat
Tech Rally: Will CG Oncology Inc stock recover after earningsInsider Buying & Risk Managed Investment Strategies - baoquankhu1.vn
Stock Traders Buy High Volume of Call Options on CG Oncology (NASDAQ:CGON) - MarketBeat
CG Oncology, Inc. $CGON Stock Holdings Trimmed by TD Asset Management Inc - MarketBeat
Lifesci Capital Predicts Stronger Earnings for CG Oncology - MarketBeat
CG Oncology (NASDAQ:CGON) Sets New 12-Month HighTime to Buy? - MarketBeat
CG Oncology, Inc. (CGON) Stock Analysis: A 39% Potential Upside in the Battle Against Bladder Cancer - DirectorsTalk Interviews
CG Oncology stock hits all-time high at 60.01 USD By Investing.com - Investing.com Australia
CG Oncology stock hits all-time high at 60.01 USD - Investing.com
CG Oncology (CGON) Valuation Check As Bladder Cancer Trial Timelines Accelerate And Cash Runway Extends To 2029 - Sahm
NMIBC Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Ferring Pharmaceuticals, FKD Therapies Oy, ImmunityBio, CG Oncology, Pfizer, UroGen Pharma, Janssen R&D - StreetInsider
CGON Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Buy Rating on CG Oncology Driven by PIVOT-006 Differentiation and 2026 Clinical, Regulatory Catalysts Supporting Favorable Risk–Reward - TipRanks
CGON: Credo shows high efficacy and durability, with regulatory and commercial plans advancing - TradingView
CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates - marketscreener.com
H.C. Wainwright raises CG Oncology stock price target to $80 By Investing.com - Investing.com Canada
H.C. Wainwright raises CG Oncology stock price target to $80 - Investing.com
AI Stocks: What is the dividend yield of CG Oncology IncJuly 2025 PostEarnings & Verified Swing Trading Watchlists - baoquankhu1.vn
Vanguard Group Inc. Has $264.93 Million Stock Position in CG Oncology, Inc. $CGON - MarketBeat
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
The Bull Case For CG Oncology (CGON) Could Change Following Surging Revenue And Deeper 2025 Losses – Learn Why - simplywall.st
What Analysts Are Saying About CG Oncology Stock - Benzinga
HC Wainwright Issues Positive Forecast for CG Oncology (NASDAQ:CGON) Stock Price - MarketBeat
CGON Stock: HC Wainwright & Co. Maintains Rating, Raises Price T - GuruFocus
Why CG Oncology Stock Is Suddenly Surging Higher - TipRanks
CG Oncology (NASDAQ:CGON) Trading Up 5.6% Following Strong Earnings - MarketBeat
CG Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
CG Oncology Q4 Net Loss Widens; Expects Cash Runway Into 2029 - marketscreener.com
CG Oncology, Inc. SEC 10-K Report - TradingView
CGON: Net loss rose to $161M as R&D and G&A costs increased; $742M cash on hand funds 12+ months - TradingView
CG Oncology (CGON) builds late-stage bladder cancer franchise on cretostimogene - Stock Titan
CGON: 2025 net loss widened to $161M as R&D ramped up, with $903M cash to fund operations into 2029 - TradingView
CG Oncology (NASDAQ: CGON) widens 2025 loss but secures $903M cash and nears Phase 3 data - Stock Titan
CG Oncology Reports Strong Cash Position and Upcoming Milestones for Cretostimogene Development in NMIBC Trials - Quiver Quantitative
Earnings Flash (CGON) CG Oncology Posts 2025 Total Revenue $4M, vs. FactSet Est of $2.8M - marketscreener.com
Earnings Flash (CGON) CG Oncology Posts 2025 Net Loss $2.08 a Share, vs. FactSet Est of $2.17 Loss - marketscreener.com
CG Oncology lines up 2026 NMIBC trial readouts with $903M cash - Stock Titan
According to the latest financial data from CG Oncology Inc., the company currently holds a total of $903 millions in cash, cash equivalents, and marketable securities. - Bitget
CG Oncology, Inc. unveils five cretostimogene research posters at ASCO GU in San Francisco - Traders Union
CG Oncology, Inc. (CGON) Stock Analysis: Unveiling a Potential 36.95% Upside in the Biotech Sector - DirectorsTalk Interviews
JP Morgan Initiates Coverage of CG Oncology (CGON) with Overweight Recommendation - MSN
CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference - The Manila Times
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):